The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 4 µg/ml. Predicted molecular weight: CEACAM1 58 , CEACAM5 77 kDa.
1/200 - 1/400.
Use 1-2µg for 106 cells.
Use 1.2µg for 106 cells.
ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.
CEACAM1 and CEACAM5 belong to the carcinoembryonic antigen (CEA) gene family. It is expressed on cells of epithelial and myeloid origin. CEACAM1 expression is downregulated in many tumors indicating a tumor - suppressive function. The antitumor effect may be due to inhibition of tumor angiogenesis, possibly by increased secretion of antiangiogenic molecules from the cells. Like all members of the CEACAM family, it consists of a single N domain, with structural homology to the immunoglobulin variable domains, followed by two immunoglobulin constant-like A (A1, A2) and one B domain. While the N, A1 and B domains can also be found in other CEA-family members, the A2 domain of CEACAM1 differs from those found in other CEACAM.
CEACAM5 is a cell surface glycoprotein that plays a role in cell adhesion and in intracellular signaling. CEACAM5 is a homodimer. It is a receptor for E.coli Dr adhesins. Binding of E.coli Dr adhesins leads to dissociation of the homodimer. Found in adenocarcinomas of endodermally derived digestive system epithelium and fetal colon.
Isoforms A, B, C: Cell membrane; Single-pass type I membrane protein.
Isoforms G, H, I: Secreted.
ab91213 at 1.2µg/106 cells in BOSC23 cells transiently transfected with an expression vector encoding either CEACAM1 (red curve) or a control protein (black curve). A PE conjugated secondary antibody was used.
ab91213 at 1.2µg/106 cells in BOSC23 cells transiently transfected with an expression vector encoding either CEACAM5 (red curve) or a control protein (black curve). A PE conjugated secondary antibody was used.
Specificity testing of ab91213. BOSC23 cells were transiently transfected with expression vectors containing either the cDNA of CEACAM1, 3, 5, 6, 8 or a recombinant transmembrane-anchored PSG1 fusion protein. Expression of the constructs was confirmed with monoclonal antibodies known to recognise the corresponding proteins (green curves). An irrelevant monoclonal antibody served as a negative control (black curves). For specificity testing, protein G purified ab91213 was tested on all CEACAM transfectants. A positive signal was obtained with CEACAM1 and CEACAM5 expressing cells (red curves).